Patents Examined by Sagar Patel
  • Imidazole-based compounds as hepatitis C virus inhibitors
    Patent number: 10959987
    Abstract: Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: March 30, 2021
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane
  • Processes for preparing phosphorodiamidate morpholino oligomers
    Patent number: 10961262
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: March 30, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Baozhong Cai, Mitchell Martini, Ross Shimabuku, Katie Thomas
  • Processes for preparing phosphorodiamidate morpholino oligomers
    Patent number: 10947533
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: March 16, 2021
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Baozhong Cai, Mitchell Martini, Katie Thomas, Ross Shimabuku
  • Oxazolidinone compounds and methods of use thereof as antibacterial agents
    Patent number: 10947205
    Abstract: The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: March 16, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mihir B. Mandal, David B. Olsen, Jing Su, Lihu Yang, Katherine Young, Takao Suzuki, Lanying You
  • Use of novel compounds for selectively extracting rare earths from aqueous solutions including phosphoric acid and associated extraction method
    Patent number: 10934604
    Abstract: The invention relates to the use, as an extraction agent for extracting at least one rare earth from an aqueous phase including phosphoric acid, of at least one compound of the following general formula (I): where n is an integer equal to 0, 1 or 2, R1 and R2 are H or an aliphatic hydrocarbon group, one of R3 and R4 has the following formula (II): where R5 and R6 are a hydrocarbon, hydroxyl or alkoxyl group, and the other one of R3 and R4 has one of the following formulas (II?) and (III): where R5? and R6? are a hydrocarbon, hydroxyl or alkoxyl group, and R7 and R8 are H or an aliphatic hydrocarbon group. The invention also relates to a method for recovering at least one rare earth using said compound, as well as to specific compounds as such.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: March 2, 2021
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Fanny Mary, Guilhem Arrachart, Stephane Pellet-Rostaing, Antoine Leydier, Veronique Dubois
  • Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
    Patent number: 10913741
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R1, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: February 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Liqi He, Sanjeev Gangwar, Yam B. Poudel, Prasanna Sivaprakasam
  • Benzathine analogs
    Patent number: 10869866
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: December 22, 2020
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Chemical compounds
    Patent number: 10851053
    Abstract: The invention is directed to substituted pyrrolidine derivatives. Specifically, the invention is directed to compounds according to Formula III: wherein A, B, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, R10, R30, Y1, Y2, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: December 1, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Anthony William Dean, Michael P. DeMartino, Hilary Schenck Eidam, Biswajit Kalita, Raghava Reddy Kethiri, Rajendra Kristam
  • Small molecule regulators of mitochondrial fusion and methods of use thereof
    Patent number: 10844023
    Abstract: Compositions comprising small molecule mitofusin agonists are described. The mitofusin modulating agents are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that regulate mitochondrial function are also described.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 24, 2020
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gerald W. Dorn, II, James Janetka
  • Endosomolytic agents for gene therapy
    Patent number: 10842884
    Abstract: Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more —NR9—, —O— or —S— linkages, R2 is —YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: November 24, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Terence Seward Baker, Michael Anthony William Eaton, Timothy John Norman, James Petrie Turner
  • Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid
    Patent number: 10836708
    Abstract: Provided herein are processes, compounds and compositions for making (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid. Also provided herein a pharmaceutical compositions containing (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 17, 2020
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Richard B. Silverman, Matthew Moschitto
  • Compositions and methods for the treatment of Parkinson's disease
    Patent number: 10829454
    Abstract: The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III, and methods for treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease such as Parkinson's disease, scleroderma, restless leg syndrome, hypertension and gestational hypertension.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: November 10, 2020
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • C-anilinoquinazoline compounds and their use in treating cancer
    Patent number: 10829479
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: November 10, 2020
    Assignee: AstraZeneca AB
    Inventors: Jason Kettle, Stuart Pearson, Martin Packer, James Smith, Tudor Grecu
  • Compounds for inhibiting NS3 and compositions containing the inhibited protein
    Patent number: 10821096
    Abstract: Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 3, 2020
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar Mansour Omar, Mahmoud Abdelkhalek El-Faky, Sameh Hamdy Abdelmageed Soror, Maan Talaat Khayat, Hani Zakariah Asfour, Faida Hassan Bamane
  • TDO2 Inhibitors
    Patent number: 10800780
    Abstract: Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: October 13, 2020
    Assignees: Genentech, Inc., NewLink Genetics Corporation
    Inventors: Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers
  • CDK2/4/6 inhibitors
    Patent number: 10800783
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: October 13, 2020
    Assignee: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
  • Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
    Patent number: 10793569
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R3, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 6, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Liqi He, Sanjeev Gangwar, Yam B. Poudel, Prasanna Sivaprakasam
  • Opioid antagonists and methods related thereto
    Patent number: 10787456
    Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, and fibromyalgia. The novel gliotoxin analog compound acts by acting as an antagonist to one or more opioid receptors, which, when present leads to the inhibition of conditions, providing increased performance over known treatments. The disclosed compounds also shows the ability to cross the blood-brain-barrier in a highly efficient manner.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 29, 2020
    Assignee: TEXAS TECH UNIVERSITY SYSTEM
    Inventors: Nadezhda German, Mohammad Anwar Hossain
  • Bicyclic compounds as ATX inhibitors
    Patent number: 10787459
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: September 29, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz
  • 2-(morpholin-4-yl)-1,7-naphthyridines
    Patent number: 10772893
    Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 15, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick